These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 3904977

  • 1. Adjuvant specific immunotherapy of resectable squamous cell lung carcinoma. Analysis at the eighth year.
    Takita H, Hollinshead A, Hart T, Bhayana J, Adler R, Rao U, Moskowitz R, Ramundo M.
    Cancer Immunol Immunother; 1985; 20(3):231-5. PubMed ID: 3904977
    [Abstract] [Full Text] [Related]

  • 2. Adjuvant, specific, active immunotherapy for resectable squamous cell lung carcinoma: a 5-year survival analysis.
    Takita H, Hollinshead AC, Adler RH, Bhayana J, Ramundo M, Moskowitz R, Rao UN, Raman S.
    J Surg Oncol; 1991 Jan; 46(1):9-14. PubMed ID: 1986150
    [Abstract] [Full Text] [Related]

  • 3. Tissue microarray evaluation of Melanoma antigen E (MAGE) tumor-associated antigen expression: potential indications for specific immunotherapy and prognostic relevance in squamous cell lung carcinoma.
    Bolli M, Kocher T, Adamina M, Guller U, Dalquen P, Haas P, Mirlacher M, Gambazzi F, Harder F, Heberer M, Sauter G, Spagnoli GC.
    Ann Surg; 2002 Dec; 236(6):785-93; discussion 793. PubMed ID: 12454517
    [Abstract] [Full Text] [Related]

  • 4. Adjuvant specific active lung cancer immunotherapy trials. Tumor-associated antigens.
    Hollinshead A, Stewart TH, Takita H, Dalbow M, Concannon J.
    Cancer; 1987 Sep 15; 60(6):1249-62. PubMed ID: 2441838
    [Abstract] [Full Text] [Related]

  • 5. Specific active lung cancer immunotherapy. Immune correlates of clinical responses and an update of immunotherapy trials evaluations.
    Hollinshead A, Takita H, Stewart T, Raman S.
    Cancer; 1988 Oct 15; 62(8):1662-71. PubMed ID: 3048633
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Effect of adjuvant immunotherapy with Nocardia rubra cell-wall skeleton in lung cancer].
    Yasumoto K, Ichinose Y, Yaita H, Tanaka K, Hara N, Ohta M, Hirota N, Nomoto K, Inokuchi K, Yamamura Y.
    Nihon Geka Gakkai Zasshi; 1983 Apr 15; 84(4):321-7. PubMed ID: 6325864
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer.
    Papachristofilou A, Hipp MM, Klinkhardt U, Früh M, Sebastian M, Weiss C, Pless M, Cathomas R, Hilbe W, Pall G, Wehler T, Alt J, Bischoff H, Geißler M, Griesinger F, Kallen KJ, Fotin-Mleczek M, Schröder A, Scheel B, Muth A, Seibel T, Stosnach C, Doener F, Hong HS, Koch SD, Gnad-Vogt U, Zippelius A.
    J Immunother Cancer; 2019 Feb 08; 7(1):38. PubMed ID: 30736848
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.